Skip to content
Vaccibody becomes Nykode.
Read more
×
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
COVID trial
Search
Investors
Financial reports and presentations
Newest first
Oldest first
Presentations
Financial reports
Webcasts
Search
Reset
05/01/2022
Company update on T cell focused COVID-19 vaccine candidate
23/11/2021
ABGSC Oncology Seminar
23/11/2021
Nykode Therapeutics company update – webcast
23/11/2021
Nykode Therapeutics company update
15/11/2021
QUARTERLY REPORT – 2021 Q3
Pages:
1
2
3
4
5
6
7
8
9
10
11
Last Page
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
Vaccibody becomes Nykode Therapeutics
Having made significant steps forward in our journey of growth and transformation, we are proud to introduce our new name, Nykode Therapeutics, and a powerful new brand identity.
